{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-199158","form_type":"8-K","ticker":"ANNX","cik":"0001528115","company_name":"Annexon, Inc.","filed_at":"2023-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.205696+00:00","generated_at":"2026-06-12T21:58:20.390697+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Annexon appoints Jamie Dananberg as CMO; ARCHER trial shows ANX007 vision protection in GA","bullets":["Jamie Dananberg, M.D., appointed chief medical officer; previously CMO at UNITY Biotechnology and exec at Takeda and Eli Lilly.","ARCHER Phase 2 trial in geographic atrophy showed ANX007 provided dose-dependent, statistically significant protection from vision loss (BCVA ≥15 letters).","Primary endpoint of GA lesion growth rate did not reach significance; additional analyses show trend toward greater effect in second six months.","ANX007 was well-tolerated with no increase in CNV or retinal vasculitis; company to discuss regulatory path with FDA later this year.","Fellow-eye analysis showed 74% (monthly) and 47% (every-other-month) reduction in BCVA loss vs sham; off-treatment data support on-treatment benefit."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-199158","json":"https://secwatch.observer/filing/0001193125-23-199158.json","markdown":"https://secwatch.observer/filing/0001193125-23-199158.md","text":"https://secwatch.observer/filing/0001193125-23-199158.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528115/000119312523199158/0001193125-23-199158-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528115/000119312523199158/d418528d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T21:58:20.390697+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}